NeoGenomics Inc (NEO) stock
Close on Nov 18, 2026Market cap $1.98BP/E –Yield –
Earnings
NeoGenomics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of NeoGenomics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 16, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026after the close | $209.00M | +11.2% | -$0.06 | $0.07 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 28, 2026after the close | $202.00M | +11.6% | $0.02 | $0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026after the close | $187.00M | +11.3% | -$0.13 | $0.01 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 17, 2026before the open | $190.00M | +10.5% | -$0.08 | $0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $188.00M | +11.9% | -$0.21 | $0.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025before the open | $181.00M | +9.7% | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025before the open | $168.00M | +7.7% | -$0.20 | $0.00 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 18, 2025before the open | $172.00M | +10.3% | -$0.12 | $0.04 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024before the open | $168.00M | +10.5% | -$0.14 | $0.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 29, 2024after the close | $165.00M | +12.2% | -$0.15 | $0.03 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024before the open | $156.00M | +13.9% | -$0.21 | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024after the close | $156.00M | +12.2% | -$0.11 | $0.03 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $152.00M | +17.8% | -$0.15 | $0.00 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $147.00M | +17.6% | -$0.19 | -$0.05 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $137.00M | +17.1% | -$0.25 | -$0.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | $139.00M | +10.3% | -$0.18 | -$0.06 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $129.00M | +6.6% | -$0.30 | -$0.14 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | $125.00M | – | -$0.28 | -$0.16 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022before the open | $117.00M | – | -$0.40 | -$0.20 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022before the open | $126.00M | – | -$0.34 | -$0.14 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $121.00M | – | -$0.17 | -$0.08 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 27, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
NeoGenomics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Consolidated revenueGAAP | FY2026 | $807.00M – $809.00M | – | New | Oct 28, 2026 |
| Consolidated revenue | FY2026 | $802.00M – $806.00M | $797.00M – $803.00M | Raised | Jul 28, 2026 |
| Consolidated revenue | FY2026 | $793.00M – $801.00M | – | New | Feb 17, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $60.00M | $55.00M – $57.00M | Raised | Oct 28, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $56.00M – $58.00M | $55.00M – $57.00M | Raised | Jul 28, 2026 |
| Net loss per diluted share (GAAP)GAAP | FY2026 | -$0.25 – -$0.23 | -$0.48 – -$0.38 | Raised | Oct 28, 2026 |
| Net loss per diluted share (GAAP)GAAP | FY2026 | -$0.32 – -$0.26 | -$0.48 – -$0.38 | Raised | Jul 28, 2026 |
| Adjusted diluted EPS (non-GAAP)non-GAAP | FY2026 | $0.21 – $0.22 | $0.16 – $0.21 | Raised | Oct 28, 2026 |
| Adjusted diluted EPS (non-GAAP)non-GAAP | FY2026 | $0.17 – $0.20 | $0.16 – $0.21 | Narrowed | Jul 28, 2026 |
| Adjusted net income (non-GAAP)non-GAAP | FY2026 | $27.00M – $28.00M | – | New | Oct 28, 2026 |
| Net lossGAAP | FY2026 | -$32.00M – -$30.00M | – | New | Oct 28, 2026 |
| Net lossGAAP | FY2026 | -$42.00M – -$34.00M | -$63.00M – -$50.00M | Raised | Jul 28, 2026 |
| Net loss | FY2026 | -$63.00M – -$50.00M | – | New | Feb 17, 2026 |
Guidance vs results
The last range NeoGenomics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $720.00M – $726.00M | $727.00MΣ4Q | Above range |
Guidance history
Every forecast NeoGenomics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 28, 2026 | Adjusted EBITDA | FY2026 | $60.00M | Raised |
| Oct 28, 2026 | Adjusted diluted EPS (non-GAAP) | FY2026 | $0.21 – $0.22 | Raised |
| Oct 28, 2026 | Net loss per diluted share (GAAP) | FY2026 | -$0.25 – -$0.23 | Raised |
| Oct 28, 2026 | Net loss | FY2026 | -$32.00M – -$30.00M | New |
| Oct 28, 2026 | Adjusted net income (non-GAAP) | FY2026 | $27.00M – $28.00M | New |
| Oct 28, 2026 | Consolidated revenue | FY2026 | $807.00M – $809.00M | New |
| Jul 28, 2026 | Adjusted EBITDA | FY2026 | $56.00M – $58.00M | Raised |
| Jul 28, 2026 | Adjusted diluted EPS (non-GAAP) | FY2026 | $0.17 – $0.20 | Narrowed |
| Jul 28, 2026 | Net loss per diluted share (GAAP) | FY2026 | -$0.32 – -$0.26 | Raised |
| Jul 28, 2026 | Net loss | FY2026 | -$42.00M – -$34.00M | Raised |
| Jul 28, 2026 | Consolidated revenue | FY2026 | $802.00M – $806.00M | Raised |
| Apr 28, 2026 | Adjusted EBITDA | FY2026 | $55.00M – $57.00M | New |
| Apr 28, 2026 | Adjusted diluted EPS (1) (non-GAAP) | FY2026 | $0.16 – $0.21 | New |
| Apr 28, 2026 | Net loss per diluted share (GAAP) | FY2026 | -$0.48 – -$0.38 | New |
| Apr 28, 2026 | Net loss | FY2026 | -$63.00M – -$50.00M | New |
| Apr 28, 2026 | Consolidated revenue | FY2026 | $797.00M – $803.00M | New |
| Feb 17, 2026 | Adjusted EBITDA | FY2026 | $55.00M – $57.00M | New |
| Feb 17, 2026 | Adjusted diluted EPS (2) (non-GAAP) | FY2026 | $0.16 – $0.21 | New |
| Feb 17, 2026 | Net loss per diluted share (GAAP) | FY2026 | -$0.48 – -$0.38 | New |
| Feb 17, 2026 | Net loss | FY2026 | -$63.00M – -$50.00M | New |
| Feb 17, 2026 | Consolidated revenue | FY2026 | $793.00M – $801.00M | New |
| Oct 28, 2025 | Adjusted EBITDA | FY2025 | $41.00M – $44.00M | New |
| Oct 28, 2025 | Adjusted diluted EPS (1) (non-GAAP) | FY2025 | $0.08 – $0.12 | New |
| Oct 28, 2025 | Net loss per diluted share (GAAP) | FY2025 | -$0.91 – -$0.84 | New |
| Oct 28, 2025 | Net loss | FY2025 | -$116.00M – -$108.00M | New |
| Oct 28, 2025 | Consolidated revenue | FY2025 | $720.00M – $726.00M | New |
| Apr 29, 2025 | Adjusted EBITDA | FY2025 | $55.00M – $58.00M | Reaffirmed |
| Apr 29, 2025 | Adjusted diluted EPS (13) (non-GAAP) | FY2025 | $0.16 – $0.20 | Raised |
| Apr 29, 2025 | Net loss per diluted share (GAAP) | FY2025 | -$0.66 – -$0.60 | Lowered |
| Apr 29, 2025 | Net loss | FY2025 | -$85.00M – -$77.00M | Lowered |
| Apr 29, 2025 | Consolidated revenue | FY2025 | $747.00M – $759.00M | New |
| Feb 18, 2025 | Adjusted EBITDA YOY % Change | FY2025 | +38% – +45% | New |
| Feb 18, 2025 | Adjusted EBITDA | FY2025 | $55.00M – $58.00M | New |
| Feb 18, 2025 | Adjusted diluted EPS (12) (non-GAAP) | FY2025 | $0.15 – $0.19 | New |
| Feb 18, 2025 | Net loss per diluted share (GAAP) | FY2025 | -$0.66 – -$0.59 | New |
| Feb 18, 2025 | Net loss YOY % Change | FY2025 | -8% – +4% | New |
| Feb 18, 2025 | Net loss | FY2025 | -$85.00M – -$76.00M | New |
| Feb 18, 2025 | Consolidated revenue YOY % Change | FY2025 | +11% – +13% | New |
| Feb 18, 2025 | Consolidated revenue | FY2025 | $735.00M – $745.00M | New |
| Nov 5, 2024 | Adjusted EBITDA YOY % Change | FY2024 | +1133% – +1233% | New |
| Nov 5, 2024 | Adjusted EBITDA | FY2024 | $37.00M – $40.00M | Raised |
| Nov 5, 2024 | Adjusted EBITDA (non-GAAP) | FY2024 | $37.00M – $40.00M | Reaffirmed |
| Nov 5, 2024 | Adjusted diluted EPS ( 14 ) (non-GAAP) | FY2024 | $0.08 – $0.10 | Raised |
| Nov 5, 2024 | Net loss per diluted share (GAAP) | FY2024 | -$0.64 – -$0.61 | Raised |
| Nov 5, 2024 | Net loss YOY % Change | FY2024 | +8% – +11% | New |
| Nov 5, 2024 | Net loss | FY2024 | -$81.00M – -$78.00M | Raised |
| Nov 5, 2024 | Net loss (GAAP) | FY2024 | -$81.00M – -$78.00M | Reaffirmed |
| Nov 5, 2024 | Adjusted net income (non-GAAP) | FY2024 | $10.00M – $13.00M | New |
| Nov 5, 2024 | Consolidated revenue YOY % Change | FY2024 | +11% – +13% | New |
| Nov 5, 2024 | Consolidated revenue | FY2024 | $655.00M – $667.00M | Raised |
| Jul 29, 2024 | Adjusted EBITDA | FY2024 | $33.00M – $37.00M | Raised |
| Jul 29, 2024 | Adjusted diluted EPS (12) (non-GAAP) | FY2024 | $0.02 – $0.07 | Raised |
| Jul 29, 2024 | Net loss per diluted share (GAAP) | FY2024 | -$0.69 – -$0.64 | Lowered |
| Jul 29, 2024 | Net loss | FY2024 | -$88.00M – -$81.00M | Lowered |
| Jul 29, 2024 | Consolidated revenue | FY2024 | $655.00M – $667.00M | Raised |
| Apr 30, 2024 | Adjusted EBITDA | FY2024 | $21.00M – $24.00M | Reaffirmed |
| Apr 30, 2024 | Adjusted diluted EPS (12) (non-GAAP) | FY2024 | $0.00 – $0.04 | Reaffirmed |
| Apr 30, 2024 | Net loss per diluted share (GAAP) | FY2024 | -$0.57 – -$0.51 | Reaffirmed |
| Apr 30, 2024 | Net loss | FY2024 | -$72.00M – -$66.00M | Reaffirmed |
| Apr 30, 2024 | Consolidated revenue | FY2024 | $650.00M – $660.00M | New |
| Feb 20, 2024 | Adjusted EBITDA | FY2024 | $21.00M – $24.00M | New |
| Feb 20, 2024 | Adjusted diluted EPS (12) (non-GAAP) | FY2024 | $0.00 – $0.04 | New |
| Feb 20, 2024 | Net loss per diluted share (GAAP) | FY2024 | -$0.57 – -$0.51 | New |
| Feb 20, 2024 | Net loss | FY2024 | -$72.00M – -$66.00M | New |
| Feb 20, 2024 | Consolidated revenue | FY2024 | $650.00M – $660.00M | New |
| Nov 6, 2023 | Adjusted EBITDA | FY2023 | -$4.00M – -$1.00M | Raised |
| Nov 6, 2023 | Adjusted diluted EPS (12) (non-GAAP) | FY2023 | -$0.18 – -$0.15 | Raised |
| Nov 6, 2023 | Net loss per diluted share (GAAP) | FY2023 | -$0.75 – -$0.71 | Raised |
| Nov 6, 2023 | revenue | FY2023 | $585.00M – $592.00M | Raised |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | -$13.00M – -$10.00M | Raised |
| Aug 8, 2023 | Adjusted diluted EPS (12) (non-GAAP) | FY2023 | -$0.28 – -$0.23 | Raised |
| Aug 8, 2023 | Net loss per diluted share (GAAP) | FY2023 | -$0.84 – -$0.79 | Raised |
| Aug 8, 2023 | Net loss | FY2023 | -$107.00M – -$100.00M | Raised |
| Aug 8, 2023 | Consolidated revenue | FY2023 | $565.00M – $575.00M | Raised |
| May 8, 2023 | Adjusted EBITDA | FY2023 | -$22.00M – -$18.00M | Raised |
| May 8, 2023 | Adjusted diluted EPS (12) (non-GAAP) | FY2023 | -$0.36 – -$0.30 | Raised |
| May 8, 2023 | Net loss per diluted share (GAAP) | FY2023 | -$0.91 – -$0.84 | Reaffirmed |
| May 8, 2023 | Net loss | FY2023 | -$116.00M – -$108.00M | New |
| May 8, 2023 | Consolidated revenue | FY2023 | $555.00M – $565.00M | New |
| Feb 23, 2023 | Adjusted EBITDA | FY2023 | -$27.00M – -$22.00M | New |
| Feb 23, 2023 | Adjusted diluted EPS (12) (non-GAAP) | FY2023 | -$0.38 – -$0.32 | New |
| Feb 23, 2023 | Net loss per diluted share (GAAP) | FY2023 | -$0.91 – -$0.84 | New |
| Feb 23, 2023 | Net loss | FY2023 | -$116.00M – -$107.00M | New |
| Feb 23, 2023 | Consolidated revenue | FY2023 | $545.00M – $555.00M | New |
| Feb 23, 2022 | Adjusted EBITDA | FY2022 | -$40.00M – -$25.00M | New |
| Feb 23, 2022 | Adjusted diluted EPS (11) (non-GAAP) | FY2022 | -$0.65 – -$0.53 | New |
| Feb 23, 2022 | Net loss per diluted share (GAAP) | FY2022 | -$1.07 – -$0.95 | New |
| Feb 23, 2022 | Net loss | FY2022 | -$133.00M – -$118.00M | New |
| Feb 23, 2022 | Adjusted net loss (non-GAAP) | FY2022 | -$81.50M – -$66.50M | New |
| Feb 23, 2022 | Consolidated revenue | FY2022 | $530.00M – $550.00M | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2021 | -$2.50M – $2.50M | New |
| Nov 4, 2021 | Adjusted diluted EPS (non-GAAP) | FY2021 | -$0.29 – -$0.25 | New |
| Nov 4, 2021 | Net (loss) income per diluted common share (GAAP) | FY2021 | -$0.01 – $0.04 | New |
| Nov 4, 2021 | Net (loss) income | FY2021 | -$800.00K – $4.20M | New |
| Nov 4, 2021 | Adjusted net loss (non-GAAP) | FY2021 | -$34.50M – -$29.50M | New |
| Nov 4, 2021 | Consolidated revenue | FY2021 | $482.50M – $487.50M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases NeoGenomics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- News
- News
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?